Tesamorelin

People run it for one thing above all: visceral, deep-abdominal fat — the hard, around-the-organs gut fat, not the pinchable subcutaneous kind. The GH/IGF-1 bump that comes with it brings the usual secondary draws (sleep, recovery, body recomposition), but the standout, and the reason it has trials at all, is the drop in visceral fat measured on CT scans.

It’s a GHRH analog like CJC-1295 — it raises your own pulsed GH rather than injecting GH — but it’s the one molecule in the family that went through pivotal Phase-3 trials and won a regulatory approval (for HIV-associated visceral fat accumulation). That’s the whole reason it stands apart in the community: the visceral-fat effect isn’t an anecdote here, it’s a measured, replicated CT endpoint. The catch people repeat is that it’s specifically a visceral-fat tool — it doesn’t do much for subcutaneous fat, and it’s daily, not a convenient weekly pin.

A stabilized analog of growth-hormone-releasing hormone (GHRH): it binds the GHRH receptor in the pituitary and increases the body’s own pulsatile GH output, which in turn raises IGF-1. Because it amplifies natural pulses rather than flooding the system with exogenous GH, the GH rhythm stays more physiological. Raised GH preferentially mobilizes visceral fat (it’s lipolytic on that depot), which is the mechanistic basis for the standout, trial-backed visceral-fat reduction — distinct from the appetite-driven fat loss of the GLP-1 class.

The trial-characterized profile is the clearest part of the story: injection-site reactions (redness, itching) are the most common, followed by the classic raised-GH cluster — fluid retention and swelling, joint pain and stiffness, and carpal-tunnel-type tingling or numbness in the hands. The one that matters metabolically is glucose: raising GH can nudge insulin resistance and blood sugar up, so it warrants watching in anyone pre-diabetic. And the standing caution that follows everything in the GH/IGF-1 family applies here too — chronically elevating IGF-1 is theoretically growth-promoting, so it’s avoided with any active or undiagnosed cancer (the approved label carries an active-malignancy contraindication).

Mostly run standalone for visceral fat — it already does the GHRH job, so it’s not paired with CJC-1295 (that would be doubling the same lever). Where it shows up in stacks, people add a GH secretagogue like Ipamorelin on the logic that GHRH raises pulse size while the secretagogue triggers the pulse — the same rationale behind the CJC+Ipamorelin pairing — but that’s a community extrapolation, not how the trials were run. The trial use was tesamorelin alone.